Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. (DXCM) is widely described in its own communications as a global leader in glucose biosensing and real-time continuous glucose monitoring (CGM) for people with diabetes. The Dexcom news stream features regular updates on product launches, clinical evidence, coverage decisions, financial performance, and leadership developments, all centered on its CGM and biosensing technology.
Investors and healthcare observers following DXCM news will find detailed announcements on new products such as the Dexcom G7 15 Day CGM System, which is designed to provide real-time glucose readings over extended wear, and Dexcom Smart Basal, a CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes using long-acting insulin. News items also cover enhancements to the Stelo app for metabolic health, AI-enabled features like meal logging, and integrations with connected devices and insulin delivery systems.
Dexcom’s news releases highlight clinical and real-world data presented at major conferences, including the European Association for the Study of Diabetes (EASD), where the company shares findings on outcomes such as pregnancy complications, diabetic ketoacidosis management, and cost-effectiveness of CGM compared to fingersticks. Coverage and reimbursement milestones, such as expanded access under the Régie de l’assurance maladie du Québec (RAMQ) and other public programs, are also frequent topics.
Financial results and guidance updates, leadership transitions, and board appointments are reported through earnings releases and Form 8-K related press announcements. For anyone tracking how CGM technology, biosensing, and digital health tools are evolving in diabetes and metabolic health, the Dexcom news page offers an ongoing record of the company’s product, clinical, and corporate developments. Bookmark this page to follow the latest DXCM press releases and regulatory disclosures as they are issued.
DexCom (Nasdaq: DXCM) has launched Dexcom Ventures, aiming to invest in innovative technologies that enhance its core diabetes monitoring business. The fund, led by Steve Pacelli, will focus on sensing technology, data analytics, and remote patient monitoring. CEO Kevin Sayer states that this move accelerates growth opportunities and supports developments in glucose sensing and metabolic monitoring. Dexcom Ventures marks the company's entry into venture capital, emphasizing its commitment to strategic investments to improve healthcare outcomes.
DexCom reported strong financial results for Q4 and the fiscal year ended December 31, 2020. Q4 revenue reached $568.9 million, a 23% increase year-over-year, while full-year revenue grew 31% to $1.93 billion. Operating income for Q4 was $104.0 million, with a GAAP operating margin of 18.3%. The company announced a strategic expansion of its sales force and secured reimbursement for its G6 CGM system in France. For 2021, DexCom projects revenue between $2.21 billion and $2.31 billion, indicating 15-20% growth.
DexCom, the leader in continuous glucose monitoring, has launched its first-ever Super Bowl commercial featuring Nick Jonas. Airing on February 7, 2021, the ad emphasizes the need for better diabetes care and aims to increase awareness about the Dexcom G6 CGM system, which eliminates painful finger pricks. The commercial highlights the outdated finger-prick method still used by millions of diabetics. DexCom plans to partner with diabetes nonprofits to promote better access to CGM technology.
DexCom, Inc. (NASDAQ:DXCM) is set to release its fourth quarter and full year 2020 financial results on February 11, 2020, after market close. A conference call will follow at 4:30 p.m. ET, available via webcast on the investor relations website. This release marks a significant opportunity for investors to assess the company's performance in the diabetes care technology sector, where DexCom is a recognized leader.
DexCom (Nasdaq: DXCM) anticipates fourth quarter 2020 revenue of at least $567 million, marking a 23% increase year-over-year. U.S. revenue is projected at approximately $451 million, a 20% rise, while international revenue could reach $116 million, up 33%. For the full fiscal year, revenue is expected to be around $1.925 billion, over 30% growth compared to 2019. Looking ahead, DexCom projects 2021 revenue of $2.21 billion to $2.31 billion, a growth of 15% to 20%, driven by sensor volume increases and international expansion.
DexCom (NASDAQ:DXCM) announces that CEO Kevin Sayer will present an update at the 39th annual J.P. Morgan Healthcare Conference on January 11, 2021. The virtual presentation is set to begin at approximately 11:40 AM EST and will be available via a concurrent webcast.
Investors can access the webcast link through the Dexcom IR website under 'Events and Presentations.' DexCom is recognized for its innovative continuous glucose monitoring (CGM) systems, aiding diabetes management globally.
DexCom, Inc. (NASDAQ:DXCM) has announced management presentations at two upcoming virtual investor conferences. Steve Pacelli, Executive Vice President of Strategy and Corporate Development, will present at the Stifel Virtual Healthcare Conference on November 16, 2020, at 11:20 AM (EST) and at the Piper Sandler Healthcare Conference on December 1, 2020, at 3:00 PM (EST). Webcasts of these events will be available on the Dexcom Investor Relations website, where they will also be archived for future access.
DexCom, Inc. (NASDAQ:DXCM) will host an Investor Day on December 9, from 8:30 AM to 11:30 AM PST. The virtual event will feature presentations from management and industry leaders discussing market opportunities, business strategy, and long-term financial outlook.
The webcast will be available without pre-registration, accessible at dexcom2020investorday.com, and a replay will follow shortly after the event concludes.
DexCom, Inc. (NASDAQ:DXCM) will host an Investor Day on December 9, from 8:30 AM to 11:30 AM PST. The event will be virtual and feature presentations from management and industry leaders discussing the company’s market opportunities, business strategy, innovation, and long-term financial outlook. A live webcast will be available without pre-registration at dexcom2020investorday.com. A replay will be accessible shortly after the event concludes.
DexCom, Inc. (Nasdaq: DXCM) reported a robust 26% revenue growth in Q3 2020, reaching $500.9 million, driven by a 29% increase in U.S. sales and a 17% rise in international revenue. GAAP operating income was $94.1 million, reflecting an 18.8% operating margin, up 470 basis points year-over-year. The company raised its full-year revenue guidance to approximately $1.9 billion, indicating 29% growth. Notable highlights include the establishment of a CGM outcomes registry and a Patient Assistance Program for those affected by COVID-19. Cash reserves stand at $2.60 billion, ensuring financial flexibility.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
